On June 1, 2021 Cellestia Biotech, specialized in targeting Transcription Factors (TFs) involved in human diseases reported that it will present updated clinical data of its ongoing Phase 1 trial at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2021 underscoring the ambition to become a leader in the field of TFs (Press release, Cellestia Biotech, JUN 1, 2021, View Source [SID1234583304]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Florian Vogl, CMO of Cellestia Biotech said: "Our clinical data at ASCO (Free ASCO Whitepaper) this year validate our transformative scientific approach and open the path for CB-103 to become a new treatment option for patients with NOTCH-driven cancers and non-oncology conditions such as autoimmune and inflammatory diseases."
Dr. Michael Bauer, CEO of Cellestia stated: "Cellestia is shifting the boundaries of biomedical research: the outstanding clinical data on CB-103 confirm Cellestia´s ability to develop novel therapies targeting Transcription Factors that historically have been considered difficult or impossible to target. We have shown we can do it and we will further expand our pipeline to address currently unmet medical needs."
Presentation details:
Title: Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers
Abstract Number: 3020
Session: Poster Discussion Session, Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology ]]Presenting Author: Elena López-Miranda, MD, Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain
Date / Time: (Virtual) Friday, June 4th, poster and recording available on demand at ASCO (Free ASCO Whitepaper).org from 9:00 AM EST A copy of the poster can be accessed on www.cellestia.com after the presentation concludes, and the recorded oral presentation will be hosted on the online ASCO (Free ASCO Whitepaper) Meeting Library. Cellestia Biotech AG Hochbergerstr. 60C www.cellestia.com CH-4057 Basel
About Cellestia’s clinical Phase 1 trial
CB103-C-101 is a Phase 1/2a multicenter, open-label, dose-escalation study with expansion arms of CB-103 in adult patients with locally advanced or metastatic solid tumors and hematological malignancies characterized by alterations of the Notch signaling pathway. The study is open for enrollment at sites in Europe and Switzerland, the US, and Asia (China, Korea).
About Transcription Factors (TF)
Transcription refers to the first step of gene expression where an RNA is created from a DNA template. Transcription factors (TF) are DNA-binding proteins that play a key role in gene transcription. Through their ability to initiate or repress site-specific transcription, each cell in our bodies can differentiate into a different cell type despite containing the same exact genetic code. Transcription factors also make genetic fine-tuning possible. Modulating the activity and the amount of transcription factor can increase or decrease the rates of the chosen gene’s transcription. Ultimately, transcription factors can be thought of as the "gatekeepers" that determine if a gene is expressed or not.